A Phase 1/2 study of Vadastuximb Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate-2 or high risk Myelodysplastic Syndrome (MDS)
|Effective start/end date||12/30/15 → 12/30/21|
- Seattle Genetics, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.